Background: Anemia is mainly attributed to nutritional deficiency, especially iron deficiency, which predominates during pregnancy, and is associated with parasitic diseases such as malaria and intestinal parasitosis,...Background: Anemia is mainly attributed to nutritional deficiency, especially iron deficiency, which predominates during pregnancy, and is associated with parasitic diseases such as malaria and intestinal parasitosis, acute or chronic diseases such as sickle cell disease, tuberculosis, HIV infection and various micronutrients disorders. It is associated with an increased risk of low birth weight and prematurity and can contribute to impaired cognitive development in early childhood, as well as to maternal mortality. The impact on the fetus is even greater if maternal anemia onset is at an early stage, or prior to pregnancy. Iron salts, such as sulfate or fumarate, are widely used in the treatment of gravidic anemia, but due to various gastrointestinal side effects, many pregnant women are not compliant with treatment. Sodium iron EDTA, on the other hand, is highly absorbable and bioavailable. The latter improves hematological values and appears to be free from the usual iron-related side effects, hence compliance with this supplementation. Objectives: To evaluate the evolution of hemoglobin levels after sodium iron EDTA supplementation at the university Clinics of Kinshasa, to determine the frequency of gravidic anemia, the dose-dependent benefit of sodium iron EDTA supplementation in pregnant women and to identify factors associated with insufficient hemoglobin gain after supplementation. Methods: This longitudinal cohort will take place in the gynecology department of the University Clinics of Kinshasa from September 2022 to August 2023 and will include at least 54 pregnant women with anemia. Conclusion: The study will enable us to better assess the benefits of sodium iron EDTA in improving hematological values, as well as its tolerability in pregnant women suffering from anemia during pregnancy in our environment.展开更多
<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effect...<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effects, poor compliance and failure of anemia treatment. To make iron more bioavailable, reduce the gastric side effects and increase the patient compliance, newer iron form, Ferric Sodium EDTA, has become available on the market. </span><b><span>Objective:</span></b><span> To assess the change in hemog</span><span>lobin level after iron supplementation with Ferric Sodium EDTA during </span><span>pregnancy. </span><b><span>Materials and Methods:</span></b><span> This is a longitudinal study concerning 337 </span><span>women attending antenatal care in maternity hospitals in the Democratic</span> <span>Republic of Congo from May to December 2020. The study included soci</span><span>odemographic and anthropometric variables along with type of feed, hemoglobin </span><span>level at recruitment and after three weeks of taking iron supplement with</span><span> Ferric Sodium EDTA (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span> syrup). For statistical analysis, we used t-test or ANOVA and chi-square test, the significance being stated at p < 0.05. </span><b><span>Results:</span></b><span> The frequency of pregnancy anemia was 51.4%. The mean </span><span>hemoglobin value of the overall study group was 8.7 ± 0.5 g/dL. The mean</span><span> maternal age and weight were 28.9 ± 6.2 years and 65.3 ± 11.7 kg, respectively. Most pregnant women (83.1%) had a diet consisting of food of plant and animal origin in equal proportions. Mean of Body Mass Index (BMI) was 24.6 ± 4.6 Kg/m</span><sup><span>2</span></sup><span> and 44.3% were overweight and obese. The co-morbidities associated were malaria and intestinal parasitosis found in 45% and 5.9% of cases, </span><span>respectively. After iron treatment with Ferric Sodium EDTA, the average</span><span> hemoglobin level increased to 11.2 g/dL with mean gain of 2.5 g/dL (p < 0.001). Pregnant women with excess weight (≥90 kg) and malaria as a comorbidity achieved a significantly lower mean hemoglobin gain (p = 0.014 and p = 0.022, respectively). Majority of women (91.2%) had not experienced the metallic taste of the syrup. </span><b><span>Conclusion:</span></b><span> Ferric Sodium EDTA as a novel iron formulation (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span>) has shown a rapid increase in hemoglobin levels in pregnant women suffering from anemia. The speedy rise in hemoglobin is related to the property of Ferric Sodium EDTA to enhance the iron absorption by inhibiting the dietary iron inhibitors. Thus, Ferric Sodium </span><span>EDTA should be used as an effective and promising iron supplement in</span><span> pregnant women with iron deficiency anemia.</span></span>展开更多
文摘Background: Anemia is mainly attributed to nutritional deficiency, especially iron deficiency, which predominates during pregnancy, and is associated with parasitic diseases such as malaria and intestinal parasitosis, acute or chronic diseases such as sickle cell disease, tuberculosis, HIV infection and various micronutrients disorders. It is associated with an increased risk of low birth weight and prematurity and can contribute to impaired cognitive development in early childhood, as well as to maternal mortality. The impact on the fetus is even greater if maternal anemia onset is at an early stage, or prior to pregnancy. Iron salts, such as sulfate or fumarate, are widely used in the treatment of gravidic anemia, but due to various gastrointestinal side effects, many pregnant women are not compliant with treatment. Sodium iron EDTA, on the other hand, is highly absorbable and bioavailable. The latter improves hematological values and appears to be free from the usual iron-related side effects, hence compliance with this supplementation. Objectives: To evaluate the evolution of hemoglobin levels after sodium iron EDTA supplementation at the university Clinics of Kinshasa, to determine the frequency of gravidic anemia, the dose-dependent benefit of sodium iron EDTA supplementation in pregnant women and to identify factors associated with insufficient hemoglobin gain after supplementation. Methods: This longitudinal cohort will take place in the gynecology department of the University Clinics of Kinshasa from September 2022 to August 2023 and will include at least 54 pregnant women with anemia. Conclusion: The study will enable us to better assess the benefits of sodium iron EDTA in improving hematological values, as well as its tolerability in pregnant women suffering from anemia during pregnancy in our environment.
文摘<strong>Background:</strong><span style="font-family:;" "=""><span> Oral iron supplements, usually in the form of ferrous salts, are associated with gastric side effects, poor compliance and failure of anemia treatment. To make iron more bioavailable, reduce the gastric side effects and increase the patient compliance, newer iron form, Ferric Sodium EDTA, has become available on the market. </span><b><span>Objective:</span></b><span> To assess the change in hemog</span><span>lobin level after iron supplementation with Ferric Sodium EDTA during </span><span>pregnancy. </span><b><span>Materials and Methods:</span></b><span> This is a longitudinal study concerning 337 </span><span>women attending antenatal care in maternity hospitals in the Democratic</span> <span>Republic of Congo from May to December 2020. The study included soci</span><span>odemographic and anthropometric variables along with type of feed, hemoglobin </span><span>level at recruitment and after three weeks of taking iron supplement with</span><span> Ferric Sodium EDTA (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span> syrup). For statistical analysis, we used t-test or ANOVA and chi-square test, the significance being stated at p < 0.05. </span><b><span>Results:</span></b><span> The frequency of pregnancy anemia was 51.4%. The mean </span><span>hemoglobin value of the overall study group was 8.7 ± 0.5 g/dL. The mean</span><span> maternal age and weight were 28.9 ± 6.2 years and 65.3 ± 11.7 kg, respectively. Most pregnant women (83.1%) had a diet consisting of food of plant and animal origin in equal proportions. Mean of Body Mass Index (BMI) was 24.6 ± 4.6 Kg/m</span><sup><span>2</span></sup><span> and 44.3% were overweight and obese. The co-morbidities associated were malaria and intestinal parasitosis found in 45% and 5.9% of cases, </span><span>respectively. After iron treatment with Ferric Sodium EDTA, the average</span><span> hemoglobin level increased to 11.2 g/dL with mean gain of 2.5 g/dL (p < 0.001). Pregnant women with excess weight (≥90 kg) and malaria as a comorbidity achieved a significantly lower mean hemoglobin gain (p = 0.014 and p = 0.022, respectively). Majority of women (91.2%) had not experienced the metallic taste of the syrup. </span><b><span>Conclusion:</span></b><span> Ferric Sodium EDTA as a novel iron formulation (Hemoforce Plus Zinc</span></span><sup><span><span><sup></span><span>®</span><span></sup></span></span></sup><span style="font-family:;" "=""><span>) has shown a rapid increase in hemoglobin levels in pregnant women suffering from anemia. The speedy rise in hemoglobin is related to the property of Ferric Sodium EDTA to enhance the iron absorption by inhibiting the dietary iron inhibitors. Thus, Ferric Sodium </span><span>EDTA should be used as an effective and promising iron supplement in</span><span> pregnant women with iron deficiency anemia.</span></span>
